|
(Ref20C15)
Effect of SiliphosŪ on chronic active hepatitis:
Study shows significant reduction in elevated liver enzymes
(and therefore hepatocellular necrosis) in just one week of
treatment with SiliphosŪ.
(Ref21C13)
Therapeutic effect of SiliphosŪ in chronic liver disease:
A small study of eight human subjects with chronic active hepatitis.
This study shows significant benefits of SiliphosŪ after just
two months treatment.
(Ref8P22)
Direct comparison of SiliphosŪ to standardized milk thistle
extract:
Study shows nearly 10x the bioavailability of SiliphosŪ over
the world's best selling standardized extract.
(Ref18C14) Useful dosages of SiliphosŪ:
Shows definite advantages of SiliphosŪ at dosages ranging from
160mg to 360mg (measured as silybin). Dose/effect relationship
is also demonstrated with the highest dosage tested getting
the most dramatic results.
(c10)
Considerably greater bioavialability of silybin as a component
of SiliphosŪ:
Laboratory study shows that binding silybin with phosphatidylcholine
on a molecular level dramatically improves its bioavailablity
on a cellular level.
(c3medline) Increased oral bioavailability
of SiliphosŪ in humans:
Human study compares SiliphosŪ and the worlds best selling standardized
milk thistle extract and shows how much better the results are
with SiliphosŪ.
(Ref9C8) Effect of SiliphosŪ on cirrhotic
patients:
Study shows that SiliphosŪ does not significantly differ in
its safe and beneficial activity in patients with cirrhosis
vs. healthy control subjects.
(Ref10C2) Long term usage of SiliphosŪ:
Study shows the beneficial properties of SiliphosŪ are not diminshed
by sustained usage of the product.
(Ref12P19) Liver damage control properties
of SiliphosŪ:
SiliphosŪ shows significant protective activity against liver
damage. This study tested SiliphosŪ protection against a variety
of toxins.
(Ref13P6)
Free radical scavenging properties of SiliphosŪ:
Study shows the capability of SiliphosŪ to scavenge free radicals
and inhibit lipid peroxidation. It also demonstrates significantly
higher blood plasma levels of silybin when administered as a
component of SiliphosŪ rather than in its unbound form.
(Ref14P13)
Effect of silimarin on lipid peroxidation:
Study shows milk thistle extract (silymarin) to be a helpful
antioxidant and silybin to be the most valuable constituent
of silymarin.
(Ref15P16) SiliphosŪ counteracts hepatotoxic
effects:
Study shows SiliphosŪ protects liver cells against free-radical
mediated toxic liver injury.
(Ref16P23) Antioxidant activity of
SiliphosŪ against alcohol:
Study shows how SiliphosŪ is dramatically more effective than
pure silybin alone. Concludes SiliphosŪ may be useful in counteracting
damage caused by alcohol intake.
(Ref19C6)
Tolerablility and effectiveness of SiliphosŪ:
Study shows high dose tolerability of SiliphosŪ as well as its
increased effectiveness over conventional standardized milk
thistle extract.
(c6medline) Liver protection potential
of SiliphosŪ:
Study shows the antioxidant and free radical scavenging effect
of SiliphosŪ.
(Ref7P12)
Comparative bioavailability of SiliphosŪ vs. silybin:
Study shows exactly how much better silybin is absorbed when
combined on a molecular level with phosphatidylcholine (a patented
process resulting in SiliphosŪ).
(Ref11P1) Liver protective activity:
Shows SiliphosŪ is more effective than its constituents, silybin
and phosphatidylcholine, alone. The effectiveness of SiliphosŪ
is considerably greater than the sum of its parts.
|
|
